VEGFA and cancer: Inhibition of vascular endothelial growth factor receptors (VEGRs) can prolong survival for patients with ovarian and other cancers.5 Cediranib, a tyrosine kinase inhibitor, is an orally bioavailable inhibitor of VEGF signaling through the VEGR1, VEGR2, and VEGR3 receptors, and it has been studied in the management of several tumors.6, 7, 8, 9